DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,409,359 | +6.0% | 118,540 | +2.5% | 0.52% | +8.5% |
| Q2 2023 | $27,756,000 | -9.3% | 115,650 | -4.7% | 0.48% | -13.5% |
| Q1 2023 | $30,588,150 | -4.2% | 121,364 | +0.8% | 0.56% | -10.3% |
| Q4 2022 | $31,941,395 | +2.9% | 120,349 | +0.1% | 0.62% | -4.6% |
| Q3 2022 | $31,042,000 | +1.1% | 120,187 | -0.8% | 0.65% | +5.0% |
| Q2 2022 | $30,709,000 | -12.1% | 121,132 | +1.7% | 0.62% | +5.3% |
| Q1 2022 | $34,940,000 | -8.5% | 119,122 | +2.6% | 0.59% | -5.0% |
| Q4 2021 | $38,181,000 | +9.9% | 116,047 | +1.7% | 0.62% | -2.1% |
| Q3 2021 | $34,744,000 | +11.2% | 114,126 | -2.0% | 0.63% | +13.6% |
| Q2 2021 | $31,254,000 | +7.3% | 116,468 | -10.0% | 0.56% | -1.6% |
| Q1 2021 | $29,124,000 | +4.0% | 129,395 | +2.6% | 0.57% | -5.4% |
| Q4 2020 | $28,004,000 | -3.6% | 126,066 | -6.5% | 0.60% | -13.5% |
| Q3 2020 | $29,036,000 | +53.9% | 134,848 | +26.4% | 0.69% | +31.9% |
| Q2 2020 | $18,871,000 | +35.3% | 106,723 | +5.9% | 0.52% | +15.2% |
| Q1 2020 | $13,949,000 | -10.0% | 100,783 | -0.2% | 0.46% | +11.8% |
| Q4 2019 | $15,497,000 | +8.2% | 100,973 | +1.9% | 0.41% | -0.7% |
| Q3 2019 | $14,317,000 | +1.5% | 99,129 | +0.5% | 0.41% | -1.0% |
| Q2 2019 | $14,100,000 | +9.6% | 98,657 | +1.2% | 0.41% | +5.3% |
| Q1 2019 | $12,866,000 | +30.3% | 97,459 | +1.8% | 0.39% | +15.6% |
| Q4 2018 | $9,877,000 | -2.3% | 95,781 | +3.0% | 0.34% | +7.9% |
| Q3 2018 | $10,105,000 | +11.8% | 92,999 | +1.5% | 0.32% | +5.4% |
| Q2 2018 | $9,042,000 | +0.3% | 91,633 | -0.5% | 0.30% | -1.3% |
| Q1 2018 | $9,019,000 | +10.5% | 92,124 | +4.7% | 0.30% | +6.3% |
| Q4 2017 | $8,165,000 | +13.4% | 87,975 | +4.8% | 0.28% | +8.8% |
| Q3 2017 | $7,201,000 | +3.7% | 83,958 | +2.0% | 0.26% | -2.2% |
| Q2 2017 | $6,944,000 | +0.6% | 82,280 | +1.9% | 0.27% | -3.9% |
| Q1 2017 | $6,905,000 | +12.2% | 80,734 | +2.1% | 0.28% | +6.5% |
| Q4 2016 | $6,156,000 | +1.8% | 79,085 | +2.5% | 0.26% | -0.4% |
| Q3 2016 | $6,047,000 | -24.4% | 77,149 | -2.6% | 0.26% | -25.3% |
| Q2 2016 | $7,997,000 | +7.8% | 79,175 | +1.3% | 0.35% | +7.3% |
| Q1 2016 | $7,416,000 | +17.9% | 78,182 | +15.4% | 0.33% | +15.1% |
| Q4 2015 | $6,289,000 | +248.2% | 67,721 | +219.4% | 0.28% | +223.9% |
| Q3 2015 | $1,806,000 | +28.3% | 21,202 | +28.8% | 0.09% | +41.9% |
| Q2 2015 | $1,408,000 | +5.0% | 16,458 | +4.2% | 0.06% | +1.6% |
| Q1 2015 | $1,341,000 | +2.8% | 15,797 | +3.8% | 0.06% | -1.6% |
| Q4 2014 | $1,304,000 | +12.8% | 15,218 | 0.0% | 0.06% | +10.7% |
| Q3 2014 | $1,156,000 | -3.5% | 15,218 | 0.0% | 0.06% | -5.1% |
| Q2 2014 | $1,198,000 | +11.6% | 15,218 | +6.3% | 0.06% | +7.3% |
| Q1 2014 | $1,073,000 | +8.9% | 14,313 | +12.1% | 0.06% | +7.8% |
| Q4 2013 | $985,000 | +11.4% | 12,763 | 0.0% | 0.05% | +6.2% |
| Q3 2013 | $884,000 | +3.2% | 12,763 | -5.7% | 0.05% | 0.0% |
| Q2 2013 | $857,000 | – | 13,533 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |